To evaluate the effect of NGFR and its potential target S100A9 on the outcomes of CRC patients after 5-FU treatment, we recruited 251 stage II/III CRC patients receiving the same standard 5-FU-based chemotherapy after surgery. The gene discussed is S100A9; the disease is colorectal carcinoma.